Josh Berick advises investment funds, strategic investors, and emerging growth and start-up companies on M&A transactions, growth equity and venture capital investments, and joint ventures, including in the health care, life sciences, and technology industries. He has extensive international experience, having led complex cross-border transactions in the United Kingdom, Europe, Asia, and Latin America.
Since joining Jones Day in 2017, Josh has represented EagleTree Capital in its acquisition of CORSAIR, Verizon Communications in the sale of cloud and managed hosting assets to IBM, Royalty Pharma in its acquisition of Arteaus Therapeutics’ royalty on Eli Lilly’s EMGALITY, GE Healthcare in its strategic partnerships with Roche (to develop an integrated digital diagnostics platform for oncology and critical care treatment) and Preventice Solutions (to develop an ambulatory cardiac arrhythmia monitoring suite), Invesco Asset Management in its PIPE investment in Evofem Biosciences, and Eni Next in its strategic investment in Commonwealth Fusion Systems.
Prior to joining the Firm, Josh represented Goldman Sachs in its investment in Odyssey Logistics & Technology Corporation, CPA Global in its acquisitions of Landon IP and Innography, Aptiv Solutions in its acquisition by ICON, Auven Therapeutics in the sale of Spirogen to AstraZeneca, 3i in the acquisition of the Active Pharmaceutical Ingredients division of Alpharma, a consortium of financial institutions including Bank of America, Goldman Sachs and Morgan Stanley in its investment in Chi-X Global, and PTT Chemical in its investment in Natureworks and related bioplastics joint venture with Cargill.
Josh is a frequent contributor to articles on Delaware and New York law issues arising in private equity and M&A transactions.
HONORS & DISTINCTIONS
The Legal 500 US: M&A/middle-market (2013-2014, 2016)
Columbia University (J.D. 1997; Harlan Fiske Stone Scholar; B.A. magna cum laude 1992)